CYTOF Altamira Therapeutics Ltd.

BEARISH Impact: 7/10 15-12G
Horizon immediate Filed Feb 27, 2026 Processed 3mo ago SEC 0001213900-26-021580
Deregistration
Final — all horizons settled through T+60d
CYTOF ▲ +12.00% at T+60d
SHORT call ✗ call lost -12.00% · α vs SPY -2.67% · entry $0.1000 → $0.1120
Last close $0.0710 (close Jun 12) · +29.00% from $0.1000 entry (call sign-flipped)
Entry anchored
Feb 27, 2026
via day open
T+1d
0.00%
call 0.00% · α -0.91%
$0.1000
settled 4mo ago
T+5d
-30.00%
call +30.00% · α +28.79%
$0.0700
settled 3mo ago
T+20d
-50.00%
call +50.00% · α +42.06%
$0.0500
settled 3mo ago
T+60d
+12.00%
call -12.00% · α -2.67%
$0.1120
settled 20d ago

Price Chart

Loading chart...

Executive Summary

Altamira Therapeutics Ltd. (CYTOF) has filed Form 15-12G to terminate the registration of its common shares under Section 12(g) of the Securities Exchange Act of 1934 and suspend its reporting obligations with the SEC. The company cites a low number of shareholders of record (approximately 48), qualifying it for deregistration under Rule 12g-4(a)(1).

Actionable Insight

Traders should anticipate reduced liquidity and limited financial disclosures going forward. The lack of ongoing SEC reporting increases information asymmetry, which may widen bid-ask spreads and increase volatility. Monitor OTC trading volume and consider exiting positions if transparency becomes a concern.

Key Facts

  • Altamira Therapeutics Ltd. is terminating the registration of its common shares under Section 12(g) of the Exchange Act.
  • The company has approximately 48 holders of record, below the 300-shareholder threshold for mandatory registration under Section 12(g).
  • No acquisition or going-private transaction is indicated; this is a voluntary deregistration due to low shareholder count.
  • The filing was effective February 27, 2026, meaning the company will no longer file periodic reports (10-K, 10-Q) or current reports (8-K).
  • Securities are expected to continue trading on the OTC market, but with reduced transparency and liquidity.

Financial Impact

Non-financial in terms of direct dollar impact, but significant in reducing disclosure and investor access to information.

transparencyliquidityreporting complianceinvestor base

Risk Factors

  • Loss of regulatory disclosure requirements increases information risk for investors.
  • Potential decline in trading volume and market maker interest due to 'going dark' status.
  • Difficulty in valuation without audited financials or management discussion.

Market Snapshot

Exchange
OTC

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
15-12G Filing (Primary)0001213900-26-021580
Document: 0001213900-26-021580-index-headers.html0001213900-26-021580
Document: 0001213900-26-021580-index.html0001213900-26-021580
Document: 0001213900-26-021580.txt0001213900-26-021580

US Market Status

Market Closed — Opens in 4h 10m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access